The combination of BRAF inhibition with downstream MEK inhibition was first shown to be of clinical value in adults with non-small cell lung cancer (NSCLC) and anaplastic thyroid cancer (60–64). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.